Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon-based treatments
dc.contributor.author | Pockros, Paul J. | en_US |
dc.contributor.author | Hamzeh, Fayez M. | en_US |
dc.contributor.author | Martin, Paul | en_US |
dc.contributor.author | Lentz, Ellen | en_US |
dc.contributor.author | Zhou, Xiaolei | en_US |
dc.contributor.author | Govindarajan, Sugantha | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.date.accessioned | 2010-10-06T14:57:13Z | |
dc.date.available | 2011-03-01T16:26:44Z | en_US |
dc.date.issued | 2010-10 | en_US |
dc.identifier.citation | Pockros, Paul J.; Hamzeh, Fayez M.; Martin, Paul; Lentz, Ellen; Zhou, Xiaolei; Govindarajan, Sugantha; Lok, Anna S. (2010). "Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon-based treatments." Hepatology 52(4): 1193-1200. <http://hdl.handle.net/2027.42/78076> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/78076 | |
dc.description.abstract | Patients with chronic hepatitis C with partial virologic response or nonresponse to interferon-based therapies can experience treatment-related improvements in liver histology. This retrospective analysis assessed the histologic response to treatment in patients with varying degrees of virologic response (sustained virologic response [SVR], breakthrough, relapse, or nonresponse), time to hepatitis C virus (HCV) RNA undetectability, and duration of viral suppression. Patients (HCV genotypes 1-6) with baseline and follow-up liver biopsies from eight phase 2 to phase 4 interferon-based trials were analyzed. Blinded biopsies were evaluated by a single pathologist. Improvements or worsening of METAVIR necroinflammatory activity and fibrosis were defined as increase or decrease of ≥1 grading category from baseline to 24 weeks after end of treatment. A majority of the 1571 patients with paired biopsy data were white, male, with HCV genotype 1/4, baseline HCV RNA levels >800,000 IU/mL, and baseline alanine aminotransferase levels ≤3 × upper limit of the normal range; mean baseline activity and fibrosis scores were 1.8 and 1.7, respectively. Overall, 80% of patients received peginterferon alfa-2a monotherapy or peginterferon alfa-2a/ribavirin combination therapy. Mean treatment duration was 46 weeks. There was a positive correlation between the degree of virologic response and improvements in METAVIR activity and fibrosis, and an inverse correlation with worsening activity and fibrosis (all comparisons, P < 0.0001). Patients with SVR had the greatest histologic benefit. As a combined group, relapsers and patients with breakthrough had significantly greater benefits than nonresponders (activity, P = 0.0001; fibrosis, P = 0.003). Consistent with these results, a better histologic response was correlated with a shorter time to undetectable HCV RNA and a longer duration of viral suppression (all comparisons, P < 0.0001). Conclusion: In patients with chronic hepatitis C who were treated with interferon-based therapies, histologic benefits may be observed even in the absence of an SVR. (H EPATOLOGY 2010;) | en_US |
dc.format.extent | 171877 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Hepatology | en_US |
dc.title | Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon-based treatments | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Scripps Clinic, La Jolla, CA ; fax: 858-554-8065 ; Division of Gastroenterology/Hepatology, Scripps Clinic, 10666, North Torrey Pines Road, La Jolla, CA 92037 | en_US |
dc.contributor.affiliationother | Genentech, Inc., South San Francisco, CA | en_US |
dc.contributor.affiliationother | Miller School of Medicine, University of Miami, Miami, FL | en_US |
dc.contributor.affiliationother | Genentech, Inc., South San Francisco, CA | en_US |
dc.contributor.affiliationother | RTI Health Solutions, Research Triangle Park, NC | en_US |
dc.contributor.affiliationother | University of Southern California–Keck School of Medicine and Liver Research Laboratory, Downey, CA | en_US |
dc.identifier.pmid | 20658462 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/78076/1/23809_ftp.pdf | |
dc.identifier.doi | 10.1002/hep.23809 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.